Quote:

---

I have to state that you were rarely right regarding your SP predictions since you started posting.

---

My only near term price predictions I have made were that it wouldn't break below .30. It has but not by much and it broke quite a bit of time after I said it wouldn't.

My longer term predictions we will see about. Those are based on the success in other indications. Having obsessively read up on the medical end I am still confident on the 95% chance of success in cancer and GVHD. With further reading I up my odds in NASH to 95% and still 85% in the other indications I have listed.

The only thing that could curtail $100 a share (or more) would be an early buyout or abysmal distribution deals.

With potential backing from the military, AMFAR and two congressmen the FDA will think twice about screwing us over again. I would expect FDA approval for June at the latest.

The one thing holding this company back is money. The only thing Cytodyn needs to do is survive until revenue. The initial stocking orders for leronlimab should be enough to cover us until prescriptions accelerate and allow us to launch new trials in other indications.

You may deem this as all speculation but it's based upon every bit of evidence I've ran across. Yes, everything could go sideways due to unforeseen factors but I think the chances of that are extremely thin.